Similarly, it has been demonstrated that both innate and acquired resistance to targeted therapies, a process that is in part characterized by dedifferentiation, can have contrasting effects on PD-L1 expression in melanoma cell lines [15, 26]. This evidence concerns the gene CD274 and melanoma.